Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Dinesh, de Alwis"'
Autor:
Graham Cohen, Bernardo Rapoport, Sze W Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P Brown, Robert M Zielinski, Eva Muñoz Couselo, Megan Lyle, James R Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs
Publikováno v:
PLoS ONE, Vol 19, Iss 11, p e0309778 (2024)
Intravenous pembrolizumab 400 mg every 6 weeks was approved across tumor types based on pharmacokinetic modeling, which showed exposures consistent with previous standard dosing of 200 mg or 2 mg/kg every 3 weeks, and early results of cohort B of the
Externí odkaz:
https://doaj.org/article/160650ac9b154127a4ad18e487432848
Autor:
Zinnia P. Parra-Guillen, Tomoko Freshwater, Youfang Cao, Kapil Mayawala, Sara Zalba, Maria J. Garrido, Dinesh de Alwis, Iñaki F. Troconiz
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
V937 is an investigational novel oncolytic non-genetically modified Kuykendall strain of Coxsackievirus A21 which is in clinical development for the treatment of advanced solid tumor malignancies. V937 infects and lyses tumor cells expressing the int
Externí odkaz:
https://doaj.org/article/fe7a797feed243a7b7e33bf75654da34
Autor:
Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain, Tomoko Freshwater
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the developm
Externí odkaz:
https://doaj.org/article/3069c7c4e0f64562b9cab9bff16d3f3d
Autor:
Olga Marchenko, Rajeshwari Sridhara, Qi Jiang, Elizabeth Barksdale, Yuki Ando, Dinesh De Alwis, Katie Brown, Laura Fernandes, Mark T. J. van Bussel, Qiuyi Choo, Michael Coory, Elizabeth Garrett-Mayer, Thomas Gwise, Lorenzo Hess, Rong Liu, Sumithra Mandrekar, Daniele Ouellet, José Pinheiro, Martin Posch, Nam Atiqur Rahman, Khadija Rerhou Rantell, Andrew Raven, Sarem Sarem, Suman Sen, Mirat Shah, Yuan Li Shen, Richard Simon, Marc Theoret, Ying Yuan, Richard Pazdur
Publikováno v:
Statistics in Biopharmaceutical Research. :1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e45310ce9d3649ab6576517e025f0859
https://doi.org/10.1080/19466315.2023.2166099
https://doi.org/10.1080/19466315.2023.2166099
Autor:
Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis, Julie A. Stone
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Abstract Background Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies;
Externí odkaz:
https://doaj.org/article/182d21e5687543179e830a09e90b9fdf
Autor:
Zinnia P Parra‐Guillén, Aymara Sancho‐Araiz, Kapil Mayawala, Sara Zalba, Maria J Garrido, Dinesh de Alwis, Iñaki F. Troconiz, Tomoko Freshwater
Publikováno v:
Clinical Pharmacology & Therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bdfcb753c6cb6ff10d883fd390c210c
https://doi.org/10.1002/cpt.2937
https://doi.org/10.1002/cpt.2937
Autor:
Kapil, Mayawala, Dinesh, de Alwis
Publikováno v:
Pharmaceutical Research. 39:1817-1822
After a drug molecule enters clinical trials, there are primarily three levers to enhance probability of success: patient selection, dose selection and choice of combination agents. Of these, dose selection remains an under-appreciated aspect in onco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b1f2e873b43f9ff9491727529c1057
https://doi.org/10.1007/s11095-022-03263-5
https://doi.org/10.1007/s11095-022-03263-5
Autor:
Grace Ramey, Santiago Vargas, Dinesh De Alwis, Anastassia N. Alexandrova, Joe Distefano, Peter Bloomingdale
We introduce the concept of optimal drug design (ODD) as the use of an AI framework to optimize the exposure, safety, and efficacy of drugs. To exemplify the concept of ODD, we developed an artificial intelligence framework that integrates de novo mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b65bcbe6722e7b752e14877711ea1c
https://escholarship.org/uc/item/7zz498wd
https://escholarship.org/uc/item/7zz498wd
Clinical holds in oncology are necessary to safeguard patients. Researchers are alerted to holds by news sources, but a systematic evaluation of clinical holds in early oncology drug development is lacking. Analysis of publicly disclosed clinical hol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9fe3f1004a1cb0a7b25faca27ef6b19
https://doi.org/10.1101/2022.06.03.22275971
https://doi.org/10.1101/2022.06.03.22275971
Publikováno v:
Nature Medicine. 28:2234-2235
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b37b380777b8b576e0ffe724fdc0f0a7
https://doi.org/10.1038/s41591-022-01975-0
https://doi.org/10.1038/s41591-022-01975-0